An international team of researchers has made CRISPR technology more accessible and standardized by simplifying its complex implementation. The simpler, faster CRISPR, which is presented in the journal Nature Communications, offers a broad platform for off-the shelf genome engineering that may lower the barrier of entry for this powerful technology.
“CRISPR technologies can be programmed to target specific sequences of genetic code and to edit DNA at precise locations, thus allowing research scientists to permanently modify genes in living cells and model organisms to explore gene function in the laboratory, including genes associated with human disease,” said co-first author Dr. David Marciano, instructor in the Olivier Lichtarge laboratory at Baylor College of Medicine.
“These technologies permit a ribonucleoprotein complex to cleave DNA at a specific sequence that base-pairs with a guide RNA in the complex. Modularity of the nucleic acid/protein complex allows researchers to specify the guide RNA sequence to target nearly any sequence. This greatly improves researchers’ ability to edit DNA,” said co-first author Dr. Toon Swings, postdoctoral scientist in the Jan Michiels laboratory at VIB-KU Leuven Center for Microbiology.
However, this approach presents some challenges, such as constraints on the sequences that can be targeted, the possibility of off-target effects and the requirement of a unique guide RNA for each target gene. Marciano, Swings and their colleagues established an international collaboration that led to a simple solution that circumvents all these issues.
“Toon and I had a set of projects in which we had to construct many mutations and guide RNAs for different genes in the bacterium E. coli. We realized we wouldn’t need a new guide RNA for each gene if we just targeted a universal sequence found in gene knockout collections. The sequence we targeted is found in many genetic collections of medically important bacteria and is even in some fruit fly collections,” Marciano said.
The researchers used a library of E. coli clones called the Keio collection. Each clone in this collection has had one gene replaced by a kanamycin resistance gene. The collection was made available in 2006 through an international collaboration between Keio University of Japan and Purdue University in the United States.
“We ended up repurposing this valuable resource by targeting the two FRT sites flanking the collection’s kanamycin cassette. This works out nicely because it gives you two cuts, which is harder to escape,” Swings said.
Their approach avoids some technical aspects of CRISPR and makes it available as an off-the-shelf ingredient for genetic engineering. It removes the need to design and clone a guide RNA and simplifies the strategy for constructing a rescue template. Also, the Keio collection can be found in laboratories across the globe and individual clones are available for a nominal fee from centralized genetic stock centers.
The new work also presents the broad utility of the approach by showing it is possible to target genes that are essential to life, to make a large collection of organisms with different mutations in a single chromosomal gene and to append new sequences onto a gene, all in the gene’s natural context. The method should complement existing techniques for genetic engineering of E. coli.
“Many model organisms, besides E. coli, have collections of gene replacements or insertions that could be targeted by a single guide RNA in a similar manner,” Swings said. “We hope our work provides a broad platform for a variety of genetic engineering approaches.”
“This is a nice example of the power of bacterial genetics. This is where CRISPR was first discovered, and now again, a different bacterial technology may make it even more useful,” said corresponding author Dr. Olivier Lichtarge, Cullen Chair of Molecular and Human Genetics, and professor of biochemistry and molecular biology and of pharmacology Baylor College of Medicine. Lichtarge also is a member of the Dan L Duncan Comprehensive Cancer Center at Baylor.
“The developed platform based on CRISPR technology will be valuable to many researchers in microbiology allowing them to perform rapid single nucleotide editing of their genes of interest or to generate chromosomal mutant collections, one of the first steps in understanding gene function,” said corresponding author Dr. Jan Michiels, group leader at VIB-KU Leuven Center for Microbiology and professor of biochemistry and molecular microbiology at the University of Leuven.
Learn more: Gene editing just got easier
The Latest on: Gene editing
[google_news title=”” keyword=”Gene editing” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Gene editing
- CFIA declares gene editing safe for livestock feedon May 3, 2024 at 1:04 pm
Leaders in Canada’s grain industry are praising the Canadian Food Inspection Agency for confirming gene edited crops are safe to use ...
- Shhh! 3 Secret Gene Editing Stocks Flying Below Wall Street’s Radaron May 3, 2024 at 11:18 am
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Gene editing stocks are among the most intriguing in the biotech scene. The ...
- Moderna Walks Away from Potential $3B Gene Editing Deal with Metagenomion May 2, 2024 at 4:37 am
Citing a strategic prioritization by Moderna, Metagenomi announced Wednesday that the partners have “mutually agreed” to terminate their gene editing agreement.
- 3 Gene Editing Stocks with the Potential to Make You an Overnight Millionaireon May 2, 2024 at 3:04 am
Pay close attention to gene editing stocks. By 2028, according to MarketsandMarkets, the market could be worth about $10.6 billion from $5.3 billion in 2023. With it, we can remove cells from the body ...
- Moderna ends gene editing alliance with Metagenomion May 2, 2024 at 12:22 am
The gene editing company Metagenomi, which went public earlier this year, said a development partnership struck with Moderna in 2021 has ended after the two companies “mutually agreed” to part ways.
- Metagenomi to regain full development rights to its wholly-owned base editing and RIGS systemson May 1, 2024 at 3:00 pm
This announcement represents a renewed opportunity to advance curative genetic medicine through the translation of Metagenomi’s broad toolbox of wholly-owned gene editing technologies, as well as a ...
- Moderna ends collaboration with CRISPR company Metagenomi, parts ways with gene editing chiefon May 1, 2024 at 1:03 pm
Moderna invested part of its vaccine windfall into a new gene-editing startup, Metagenomi. Now it's backing out.
- Moderna exits gene editing deal worth up to $3B biobucks, leaving Metagenomi in the spotlighton May 1, 2024 at 1:00 pm
Earlier this year, Metagenomi had the spotlight with a $93.7 million IPO. Now, Moderna is exiting stage left on a partnership worth up to $3 billion in biobucks.
- Prime Medicine Gets FDA Okay for First Trial of Gene Editing Techniqueon April 30, 2024 at 8:27 am
The FDA has cleared a clinical trial of an ex vivo prime editing candidate in patients with a rare disease, Prime Medicine announced Monday. The technique taps CRISPR technology to rewrite defective ...
via Bing News